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Background: In oncology, pain control is a persistent problem. Significant
barriers to cancer pain management are patient related. Pain self-management
support interventions have shown to reduce pain intensity and patient-related
barriers. Comparative effectiveness research is a suitable approach to test whether
effects are sustained in clinical practice. Objective: In this pilot randomized
controlled trial, the implementation of the ANtiPain intervention into clinical practice
was tested to assess the effects on pain intensity, function-related outcomes,
self-efficacy, and patient-related barriers to pain management to prepare a larger
effectiveness trial. Methods: Within 14months, 39 adult oncology patients with
pain scores of 3 or higher on a 10-point numeric rating scale were recruited in an
academic comprehensive cancer center in Southern Germany. Patients in the control
group (n=19) received standard care. Patients in the intervention group (n=20)
received ANtiPain, a cancer pain self-management support intervention based on
3 key strategies: provision of information, skill building, and nurse coaching. An
intervention session was performed in-hospital. After discharge, follow-up was
provided via telephone calls. Data were collected at baseline and 1 and 6 weeks
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after discharge. Effect sizes were calculated for all outcomes. Results: Large
effects were found for activity hindrance (Cohen d=0.90), barriers (d=0.91), and
self-efficacy (d=0.90). Small to moderate effects were found for average and worst
pain (Cohen d=0.17-0.45). Conclusions: Key findings of this study involved
function-related outcomes and self-efficacy. Implications for Practice: Because
these outcomes are particularly meaningful for patients, the integration of ANtiPain
to routine clinical practice may be substantial. A larger study will be based on
these findings.
n Background
The Problem
Depending on type and stage of the illness, 30% to 75% of
oncology patients experience pain.1 Despite highly effective
therapies,2,3 pain control is a persistent problem in cancer
patients.4 Significant barriers to cancer pain management are
patient related.5,6 Common patient issues arise from a lack of
information and fears related to pain medication that are deeply
rooted in modern society.5 Indeed, concerns over drug tolerance
and addiction are 2 frequently named examples.5 Furthermore,
patients may lack skills and knowledge to carry out appropriate
cancer pain self-management.6 These challenges are compounded
by the fact that cancer treatment is increasingly being shifted to
the outpatient setting, leaving patients in charge of their pain
management at home. Thus, patients’ self-management is of
growing importance for a successful pain treatment.
Pain Self-management Support
Pain self-management support interventions are known not
only to have significant and clinically relevant effects on patient-
related barriers to cancer pain management7,8 but also to in-
crease pain-related self-efficacy7,9 and to decrease pain intensity
moderately.10Y14 The effect of these interventions on pain
intensity (mean 1.1 reduction on an 11-point numeric rating
scale [NRS] from 0=no pain to 10=worst imaginable pain) is
slightly higher than some analgesic agents, like paracetamol or
gabapentin, that are frequently added to opioid therapy for
pain management.11 Notably, such a reduction is higher than
the commonly accepted threshold for the ‘‘minimal clinically
important difference’’ in pain management.15 These effects are
even seen if pain treatment is prescribed by specialized pain
physicians, which guarantees that patients have optimal medi-
cal pain therapy available.16 It can thus be assumed that self-
management support interventions significantly add to the
effect of state of the art pharmacological pain management.
Considering the absence of toxicity, cancer pain self-management
support interventions may become an important component of
cancer pain management routines.14
However, the clinical applicability of cancer pain self-
management support interventions in routine clinical care has
not yet been the focus of research,10Y13 as these have mostly
been tested in highly controlled settings (ie, randomized con-
trolled trials [RCTs]), with rather rigid inclusion and exclusion
criteria, that do not fully reflect the variability in patients, providers,
and practice patterns in various settings.
Moreover, cancer pain self-management support interven-
tions are so-called ‘‘complex interventions’’ that target behavior
change of oncology patients with pain. Complex interventions
are interventions that consist of several interacting components.17
Complexity is increased by a high number of interacting inter-
vention components as well as other factors, such as the number
and difficulty of behaviors required by those delivering or
receiving the intervention, as well as the degree of flexibility
or tailoring of the intervention permitted.17 In the past, the
quality of reporting complex interventions that target behavior
change has been low. Therefore, Michie et al18 provided a
taxonomy to describe behavior change interventions, such as
cancer pain self-management support interventions. It is known
that complex interventions are highly sensitive to local con-
textual features such as staff morale and competence as well as
available resources.17 Therefore, comparative effectiveness re-
search is a useful approach to assess the effectiveness of cancer pain
self-management support interventions in clinical practice.17
Target Outcomes for Pain Self-management
Support Intervention Research
In the past, most trials focused mainly on traditional outcome
measures such as pain intensity.14 However, it is known that
patients may consider other outcomes more important, such
as the interference of pain with other dimensions of life (eg,
interpersonal relationships).19 Because pain self-management
support interventions target these outcomes of interest, it has
been recommended to integrate function-related outcomes in
pain self-management research.19,20
Development of the ANtiPain Intervention
In German-speaking countries, interventions to support cancer
pain self-management are largely unknown. Therefore, we
translated and adapted the PRO-Self Plus Pain Control
Program (PCP) by Miaskowski et al7 that was successfully
tested in the United States for the German context. The 10-week
PRO-Self Plus PCP was based on 3 key strategies (information,
skill building, and nurse coaching). It was implemented by
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master’s-prepared oncology nurses in the outpatient setting
during face-to-face home visits (biweekly) and telephone calls
(every other week). Information was provided using academic
detailing, an educational strategy that allows tailoring the infor-
mation to the participants.21 In addition, the PRO-Self Plus
PCP included core principles like assessing baseline knowledge,
defining goals, providing correct medical information, discuss-
ing controversial issues, encouraging active participation, using
educational materials, and providing reinforcement in follow-up
sessions.22
The German version of the 10-week program was pilot tested
at the Tumorzentrum Ludwig HeilmeyerYComprehensive Cancer
Center Freiburg.22Y24 To implement complex interventions,
usually, adaptations are required to ensure a proper fit with the
individual setting in routine clinical care. For this, interven-
tions can be conceptualized as having ’core components’ (ie,
indispensable elements of the intervention) and an ‘‘adaptable
periphery’’ (eg, structures and systems).25 Results of the pilot
RCT provided the information to adapt the PRO-Self Plus
PCP. The changes that were made to the PRO-Self Plus PCP
were of a structural kind while the core of the PRO-Self Plus
PCP intervention was maintained (eg, 3 key strategies). The
adapted intervention was called ANtiPain and is described in
detail in Table 1. ANtiPain is a clinically, more feasible, and
cost-effective intervention in the local German context.26 To be
a good fit for as many practice settings as possible, ANtiPain was
conceptualized so that the first contact with the patients could
be made in both the inpatient and outpatient setting. In addi-
tion, as master’s-prepared oncology nurses are scarce in Germany,
ANtiPain was designed to be implemented by experienced
bachelor-prepared oncology nurses who work in the clinical
setting. For this study, the first contact was made during an in-
hospital stay with the patients. Follow-up telephone calls were
chosen instead of home visits after discharge in view of the costs.
In addition, the option for visits with the intervention nurse during
outpatient or inpatient routine follow-up (eg, with their treating
physician) was provided.
Objectives
The main objective of this pilot RCT was to test the effect of the
implementation of the ANtiPain intervention in the clinical
setting on pain intensity, function-related outcomes, self-efficacy,
health-related quality of life (HRQoL), and patient-related barriers
to pain management to prepare a larger effectiveness trial.
n Methods
Setting and Sample
In a randomized controlled pilot study of adult oncology, inpa-
tients of a palliative care consultation service at the University
Medical Center Freiburg, Germany, were recruited. The
inclusion criteria were that patients had pain scores of 3 or higher
out of 10, they needed to self-manage their pain after discharge,
had a life expectancy greater than 3months as assessed by the
treating physicians, and could understand, read, and write German.
Patients were excluded if the treating physician perceived severe
cognitive deficits that would prevent patients from participating
actively in self-management support.
Interventions
CONTROL GROUP
The hospital’s palliative care consultation service or the acute
pain management service recommended treatment following
state of the art guidelines.2 In addition, patients in the control
group (CG) received routine cancer care that did not include
any standardized cancer pain self-management support. After
the 6-week study period, patients in the CG were offered pain
self-management support by one of the intervention nurses.
INTERVENTION GROUP
Patients in the intervention group (IG) also received a recom-
mendation for state-of-the-art pain treatment by either the
hospital’s palliative care consultation service or the acute pain
management service. In addition, patients in the IG participated
in the ANtiPain intervention, which is described in detail fol-
lowing the taxonomy of Michie et al18 in Table 1. If family
caregivers were involved in pain self-management, they were
invited to take part in the intervention. The ANtiPain inter-
vention included structured and tailored components and was
based on 3 key strategies: information, skill building, and nurse
coaching. It was performed following a detailed intervention
protocol by at least bachelor-prepared oncology nurses who
were part of the clinical team in the oncology department. The
intervention consisted of an in-hospital visit before discharge
and telephone calls after discharge. In-person visits after dis-
charge were scheduled only if patients had routine follow-up visits
due to their cancer treatment. Laminated cards were used to visualize
the intervention’s content for the patients. Patients received a
corresponding booklet that summarized the information from
the intervention session and a pillbox to organize their oral
medication. Time and duration of the follow-up phone-calls
were tailored individually according to a standardized clinical
algorithm that was based on patient-reported pain intensity,
satisfaction with pain management, and adherence to the analgesic
regimen (see Table 1).
QUALITY ASSURANCE OF THE INTERVENTION
In 2 one-to-one sessions, the intervention nurses were trained by
the first author (A.K.) to perform the intervention by following
a detailed intervention protocol. Ongoing quality assurance of
fidelity with the intervention protocol was performed by peer
review of the intervention nurses. The first intervention session
of each intervention nurse was audio recorded and a second
intervention nurse checked the audio file for protocol fidelity.
With this method, at least 95% protocol fidelity was reached as
assessed by the intervention nurses. In addition, the intervention
nurses noted timing, duration, and content of each intervention
session and kept field notes in which they noted all relevant
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Table 1 & Literature-Based Description of ANtiPain Intervention With 3 Key Strategies (Information, Skill
Building, Nurse Coaching) Following the Taxonomy of Michie et al18 Derived From Koller et al26
Cluster Label of
Michie et al18 TechniquesofMichie et al18 ANtiPain Intervention Component Example26
Time Point of
Intervention
(3) Repetition and
substitution
Generalization of target
behavior [8.6]
Information about individual analgesic prescription and co-medication
including optimal time points of prescribed analgesics during 24h
IH, Tf-u
Information about side effects and side effect management
Information printed in corresponding booklet for patients
Habit formation [8.3] Skill building and nurse coaching: Supporting the implementation of
analgesic intake into daily routine
IH, Tf-u
Habit reversal [8.4] Skill building and nurse coaching: Correcting analgesic intake time-points
during the day
Tf-u
Behavioral rehearsal/
practice [8.1]
Skill building and nurse coaching: Checking and correcting daily practice
of analgesic intake
Tf-u
(4) Antecedents Restructuring the physical
environment [12.1]
Skill building: Implementing weekly medical pillboxes IH
Restructuring the social
environment [12.2]
Information: Addressing barriers to pain management of family caregivers IH, Tf-u
Distraction [12.4] Nurse coaching: Addressing nonadherence with recommendations and
considering solutions with participants
Tf-u
(7) Natural
consequences
Health consequences [5.1] Information: Health consequences if pain is persistently high IH, Tf-u
Skill building: Self-monitoring of pain and side effects
(8) Feedback and
monitoring
Feedback on behavior [2.2] Nurse coaching: Giving feedback on analgesic intake Tf-u
Other(s) monitoring with
awareness [2.1; 2.5]
Skill building: Family caregivers are invited to give feedback IH, Tf-u
Self-monitoring of
behavior [2.3]
Skill building: Patients are asked to self-monitor their analgesic intake IH, Tf-u
Self-monitoring of outcome
of behavior [2.4]
Skill building: Patients are asked to self-monitor the effects of their
analgesic intake on pain and side effects
Tf-u
(9) Goals and
planning
Action planning (including
implementation
intentions) [1.4]
Information and nurse coaching: Discussion about cancer pain self-
management techniques that may be implemented into daily practice
IH, Tf-u
Problem solving/coping
planning [1.2]
Nurse coaching: Supporting patients to find solutions to everyday
problems with pain management
Tf-u
Goal setting (behavior
and outcome) [1.3]
Information and nurse coaching: Setting a maximum pain level as target
outcome for cancer pain self-management
IH, Tf-u
Discrepancy between current
behavior and goal [1.6]
Nurse coaching: Relating achieved or not achieved target pain level with
pain management behavior in a discussion with patient
Tf-u
Algorithm to stop intervention: Stopping intervention if patient is satisfied
with pain management and pain level e3 and patient adheres with pain
management recommendations
Review behavior and
outcome goal(s) [1.5; 1.7]
Nurse coaching: Reflecting with patient implemented and not
implemented daily pain management behavior
Tf-u
Nurse coaching: Clinical algorithm to tailor timing of intervention
sessions (patients are asked at the beginning of each telephone call
whether pain was G3; if they were satisfied with the pain management;
and if they were able to adhere to the analgesic prescription. If 1
question is answered with ‘‘no,’’ the next telephone call is scheduled. If
all questions are answered with ‘‘yes’’ for 2 wk in a row, the
intervention is ended)
(10) Social support Practical, general, and
emotional social
support [3.1Y3.3]
Nurse coaching: Inclusion of family caregivers IH, Tf-u
(12) Self-belief Verbal persuasion and
role modeling [15.1]
Information and nurse coaching: The intervention nurse uses academic
detailing technique21 and model-patient examples from intervention
protocol underlined with her practical experience to address
patient-related barriers to cancer pain management.
IH, Tf-u
(continues)
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issues regarding study procedures. The latter were discussed in
monthly research meetings with the study coordinator (S.W.).
Measurements
The objective of this study was to assess the intervention’s effect
on relevant outcomes such as pain intensity, function-related
outcomes (ie, pain interference with daily activities and pain-
related activity hindrance), pain-related self-efficacy, HRQoL,
and patient-related barriers to cancer pain management. Figure 1
shows the research model that underlies the measurement plan
of this pilot study. A more detailed description of the psy-
chometric properties of the listed instruments can be found
elsewhere.26 Demographic and clinical data, functional status,
depression, daily opioid intake, as well as the dose of the inter-
vention were measured as covariates.
For pain intensity, 9 items from the Brief Pain Inventory
(BPI) were used to measure average and worst pain intensity
Figure 1n Research model that illustrates the proposed relationships tested in the ANtiPain pilot study. Study measurements are
noted in boxes with dashed lines; BQII-G: German version of the Barriers Questionnaire II; HRQoL: Health-related quality of life; SES:
Self-efficacy scale.
Table 1 & Literature-Based Description of ANtiPain Intervention With 3 Key Strategies (Information, Skill Building,
Nurse Coaching) Following the Taxonomy of Michie et al18 Derived From Koller et al26, Continued
Cluster Label of
Michie et al18 Techniques ofMichie et al18 ANtiPain Intervention Component Example26
Time Point of
Intervention
(16) Regulation Regulate negative
emotions [11.2]
Information: The intervention nurse uses academic detailing technique21
to address patient-related cognitive barriers to cancer pain management.
IHIH, Tf-u
Pharmacological support
[11.1]
Information: Individualized correct medical information is given the
patients about their analgesic prescription and patients are given a
detailed written analgesic medication plan.
Abbreviations: IH, in-hospital (shortly before discharge); Tf-u, telephone follow-up (following a clinical algorithm that was triggered by patient satisfaction with
cancer pain self-management, pain level, and patient adherence; telephone call is scheduled if 1 of the questions is answered unsatisfactorily, and the intervention
is stopped when for 2 weeks in a row, all questions are answered satisfactorily).
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and pain interference with daily activities.27 In the BPI, worst
and average pain intensities are measured with an 11-point
NRS: 0 (no pain) to 10 (worst pain imaginable).
For function-related outcomes, pain interference with daily
activities is a 7-item scale within the BPI in which patients are
asked to evaluate on 11 point NRS (0=no interference and
10=complete interference) with 7 daily activities such as sleep
or walking ability. In addition, the self-developed item from
a previous study was used to measure pain-related activity
hindrance,22 by asking the patients to rate ‘‘The pain hindered
me to do things that I wanted to do today’’ on a 0 (not at all)
to 10 (completely) NRS.
Pain-related self-efficacy was measured with the German
version of the Pain Self-efficacy Questionnaire.28 Patients rated
each of the 10 items regarding their self-confidence to manage
a number of aspects of their pain on a 7-point NRS (0=very
uncertain to 6=very certain).
Health-related quality of life was measured with the Medical
Outcome Study Short-Form, a 12-item self-report tool that
is commonly used and well validated.29,30 Items are scored on
3- and 5-point Likert scales and summed up to 2 subscales
(physical and mental).
Patient-related barriers to cancer pain management were measured
with the German version of the Barriers Questionnaire II, which is
a self-report questionnaire with 27 items addressing 8 common bar-
riers (eg, concerns about addiction).31,32 Items are recorded on 6-
point Likert scales with 0 (do not agree at all) and 5 (agree very much).
Functional status was rated by the patients with the German
version of the Eastern Cooperative Oncology Group Performance
Status (ECOG-PS), which measures the patient’s capacity to
perform a variety of activities that are normal for most people.33,34
Depression was measured with the Patient Health Ques-
tionnaire, a 2-item screening tool35 that assesses decrease of
interest and dejectedness each on a 0 (never) to 3 (almost
every day) NRS. For analgesic medication, within the BPI,
patients listed their around-the-clock and as needed analgesic
medication. Daily opioid intake was calculated as the daily
dose equivalent of oral morphine, according to opioid
conversion ratio tables. The dose of intervention was measured
as the time that was spent with the patient and was noted in
hours and minutes by the intervention nurses at each session
and telephone call.
Data Collection Procedures
Patients were approached during their routine hospital stay
and invited to participate if inclusion criteria applied. After
providing written informed consent, patients were first asked
to complete the baseline questionnaire (T0) to obtain unbiased
data with regard to group allocation. Then, patients were ran-
domized 1:1 into the IG and CG by using a computer-
generated list with randomly permuting block lengths. Opaque
envelops were prepared by an uncommitted study nurse (was
not involved in recruitment or intervention) who arranged them
in a box accessible to recruiting personnel. Therefore, recruiting
personnel was blinded to group allocation. Follow-up data collection
was performed via mail with patient self-report questionnaires 1 (T1)
and 6 (T2) weeks after discharge. It was organized by study nurses
who were blinded to group allocation. For T1, patients were given
the questionnaires and prestamped and addressed envelopes at
discharge. Four to 6 days after hospital discharge, a study nurse
contacted the patients via telephone as a reminder to return the
completed questionnaires. For T2, questionnaires were sent
together with a prestamped and addressed envelope. A study
nurse contacted the patients via telephone first, to announce the
third questionnaire, before sending them, and second, to
remind them to send back the completed questionnaires at T2.
Data Analysis
Descriptive statistics were applied as appropriate. Line diagrams
were drawn for all outcomes.
EFFECT SIZES
To assess the magnitude and clinical significance of the effects, 2
different measures for effect sizes were applied. The linear mixed
model (LMM) that is applied in this study for longitudinal data
analysis does not yield information on the sizes of found ef-
fects. Therefore, we calculated within-group changes over time
(change scores) and then compared these change scores between
groups. This means that Cohen d was calculated for between-
group differences of the change score for those patients who
completed the baseline, and at least 1 more questionnaire (T1 or
T2) for the respective time point. Cohen d was calculated for
primary and secondary outcomes (for $T1 to T0 and $T2
to T0, respectively), with d=0.2 representing a small, d=0.5 a
moderate, and d=0.8 a large effect in favor of the IG. In addition,
to assess clinically meaningful differences in the 2 groups, we
calculated the proportion of patients who achieved the clinically
important difference of 30% improvement for each group for
each outcome to compare them between the IG and the CG.15
STATISTICAL SIGNIFICANCE
We also applied an LMM to determine statistical differences
between the 2 groups, regarding the outcomes with treatment
as binary and time as continuous covariate, their interaction
as fixed effects and the intercept and time as random effects.
Significance of treatment effects were assessed by testing the
interaction term. The level of significance was set at .05.
n Results
Between December 2013 and January 2015, 39 patients (44%
women) were recruited (Figure 2). The 2 groups did not differ
in baseline characteristics (Table 2). The mean (SD) age of
patients was 57 (10.6) years and a median school education of
10years (25/75 percentile=9/13). At inclusion, the mean func-
tional status (ECOG) was 2.8, which means that, on average,
patients were not able to leave their bed for more than 50%
of daytime. Mean (SD) baseline average pain intensity was 4.4
(1.5), and mean (SD) baseline worst pain intensity was 7.9
(1.4). Over the time of the study, the daily opioid dose of
patients in the IG decreased slightly compared to the patients in
6 n Cancer NursingTM, Vol. 00, No. 0, 2017 Koller et al
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the CG (T1 d=j0.28; T2 d=j0.38). Whereas for all patients,
the functional status decreased over the course of the study, it
decreased slightly more in the IG (ECOG T0 IG: 2.95, CG:
2.59; T1 IG: 2.36, CG: 2.11; T2 IG: 1.59, CG: 2.14).
Effect Sizes
COHEN d
Line diagrams of all outcomes over the course of the study
are shown in Figure 3. Cohen d of average and worst pain
intensity ranged between 0.17 (T1 average pain) and 0.45 (T2
average pain), representing small to moderate effects (Table 3).
Large effects (d90.8) were found for the function-related
outcome ‘‘pain-related activity hindrance’’ at T2 (d=0.9), for
patient-related barriers to pain management (d=1.62 at T1 and
d=0.91 at T2), and self-efficacy at T2 (d=0.92; Table 3).
Patients in the IG also reported moderately lower interference
with daily activities (T1, d=0.6; T2, d=0.77) and moderately
increased physical/mental HRQoL (T1, d=0.32/0.54; T2,
d=0.57/0.38) compared with patients in the CG.
CLINICALLY IMPORTANT DIFFERENCE
The proportion of patients who reported an improvement in
average pain of 30% or greater at T2 was 84.8% in the IG
versus 64.3% in the CG (¸IG-CG: 20.5%; Table 4). For
worst pain intensity, the proportion with an improvement of
Figure 2n Flow of participants during the course of the study.
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30% or greater was 54.5% in the IG, compared with 50.0%
in the CG at T2 (¸IG-CG: 4.5%). For pain interference
with daily activities, 40.4% more patients in the IG reported an
improvement of more than 30%, compared with patients in the
CG (83.3% in the IG vs 43.9% in the CG). The proportion of
patients with an improvement in patient-related barriers of 30%
or greater was higher in the IG than in the CG (58.3% in the IG
vs 0% in the CG at T2).
Statistical Significance
Applying the LMM, a significant effect on patient-related
barriers toward pain management (P=.03) was found, which
means that barriers decreased statistically more in patients
from the IG than for patients in the CG. The effects on the
other outcomes were statistically not significant (Table 3).
n Discussion
To our knowledge, this is the first study to pilot test the imple-
mentation of a cancer pain self-management support intervention
into clinical practice. Results indicate that the intervention may
have highly valuable effects, particularly on outcomes that are
essential from a patient perspective (eg, pain interference with
daily activities, self-efficacy, patient-related barriers). However,
although study and intervention procedures were feasible in
Table 2 & Demographic and Clinical Baseline Characteristics of Patients
Variable IG CG Total P
Number of participants n 20 19 39
Age in years Mean (SD) 55.3 (10.2) 58.1 (11.2) 56.6 (10.6) .4
Female sex % (n) 60.0 (12) 36.8 (7) 48.7 (19) .21
Live alone in household % (n) 30.0 (6) 31.6 (6) 30.8 (12)
Marital status, % (n) Married 60.0 (12) 47.4 (9) 53.8 (21) .71
Widowed 5.0 (1) 15.8 (3) 10.3 (4)
Separated 15.0 (3) 15.8 (3) 15.4 (6)
Unmarried 20.0 (4) 21.1 (4) 20.5 (8)
Years of school education Median (quartiles) 11 (9/13) 10 (9/13) 10 (9/13) .53
Months since diagnosis Median (quartiles) 6 (3/34) 9 (1/36) 8 (2/34.5) .77
Diagnosis, % (n) Gastrointestinal 30.0 (6) 36.8 (7) 33.3 (13) .28
Breast and gynecological 45.0 (9) 21.0 (4) 33.3 (13)
Other (including lung, Multiple
Myeloma, etc.)
25.0 (5) 42.1 (8) 33.3 (13)
Therapeutic goal, % (n) Curative 50.0 (10) 52.6 (10) 51.3 (20) .59
Palliative 35.0 (7) 42.1 (8) 38.4 (15)
Missing 15.0 (3) 5.3 (1) 10.3 (4)
Months of pain duration Median (quartiles) 10 (2/35.3) 3.5 (1/12.3) 5.0 (1.8/23.3) .19
Pain pattern, % (n) Permanent pain with little fluctuation 5.0 (1) 26.2 (5) 15.4 (6) .12
Permanent pain with strong fluctuation 50.0 (10) 47.4 (9) 48.7 (19)
No permanent but breakthrough pain 45.0 (9) 21.1 (4) 33.3 (13)
Missing 5.3 (1) 2.6 (1)
ECOG Mean (SD) 2.95 (0.91) 2.59 (0.87) 2.78 (0.90) .24
Depression score (PHQ2) Mean (SD) 3.05 (1.88) 2.61 (1.24) 2.84 1.86 .5
Patient preference, % (n) Strongly preferred IG 45.0 (9) 52.6 (10) 48.7 (19) .88
Strongly preferred CG 5.0 (1) 5.3 (1) 5.1 (2)
No preference 50.0 (10) 42.1 (8) 46.2 (18)
Patients who dropped out % (n) 40.0 (8) 26.0 (5) 33.3 (13) .5
Baseline questionnaire only % (n) 25.0 (5) 21.1 (4) 23.1 (9) .77
Average pain T0 Mean (SD) 4.0 (1.56) 4.9 (1.41) 4.4 (1.54) .15
Worst pain T0 Mean (SD) 7.6 (1.39) 8.2 (1.43) 7.9 (1.42) .07
Pain interference with function T0 Mean (SD) 6.0 (2.10) 5.6 (2.00) 5.8 (2.03) .32
Pain-related activity hindrance T0 Mean (SD) 5.2 (4.05) 5.9 (3.49) 5.5 (3.78) .74
QoL physical health T0 Mean (SD) 27.1 (8.61) 26.3 (6.05) 26.7 (7.39) .73
QoL mental health T0 Mean (SD) 42.9 (12.02) 45.9 (7.91) 44.3 (10.21) .22
Patient-related barriers to pain
management T0
Mean (SD) 3.2 (0.84) 2.8 (0.46) 3.04 (0.70) .14
Self-efficacy scale T0 Mean (SD) 3.1 (1.48) 3.1 (1.01) 3.1 (1.26) .76
P = .05.
Abbreviations: IG, intervention group; CG, control group; ECOG, Eastern Cooperative Oncology Group Performance Status; PHQ2, Patient Health
Questionnaire-2; T0, measured at baseline; QoL, quality of life.
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general, some aspects (eg, optimizing the recruitment of patients
with cancer-related pain) may need additional consideration for
the planning of future trials.
When asked to participate, 37% of patients declined participa-
tion. This rate was low compared with other studies on cancer pain
self-management support,8,36,37 even though patients in our study
Figure 3n Line diagrams of outcome variables over the course of the study for patients who completed at least baseline and 1more questionnaire.
Pilot Test of a Pain Self-management Support Intervention Cancer NursingTM, Vol. 00, No. 0, 2017 n9
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
had a low baseline functional status (mean ECOG, 2.8). This
may indicate that from the perspective of a large proportion of
cancer patients, the intervention targeted a relevant issue but may
not be applicable or valued by all patients.
In this study, the retention of participants was exceptionally
challenging (dropout rates were quite high [23% at T1 and 33%
at T2]). These dropout rates, however, are comparable with
those in other studies with palliative care patients who
oftentimes present with a permanently decreasing health
status.38 The high mortality rate in this study was surprising given
the fact that the expected 3-month longevity was an inclusion
criterion. However, it is known that even when researchers do
Table 3 & Cohen d and Change Scores of Outcomes (Pain, Function, and Health-related Quality of Life) and
Covariates (Self-efficacy and Patient-related Barriers Toward Pain Management) as well as P Values
of the LMM
Cohen da
IG CG
P LMMbn Mean SD n Mean SD
Average pain T1 0.17 14 j1.43 1.95 11 j1.09 1.97
Average pain T2 0.45 11 j2.45 1.51 14 j1.71 1.77 .55
Worst pain T1 0.23 14 j2.86 2.35 11 j2.09 4.06
Worst pain T2 0.34 11 j4.27 2.41 14 j3.14 4.00 .36
Pain interference with function T1 0.60 14 j2.12 2.35 12 j0.22 3.79
Pain interference with function T2 0.77 11 j4.05 2.79 14 j1.70 3.29 .08
Pain-related activity hindrance T1 0.32 13 j3.15 3.69 12 j2.14 2.41
Pain-related activity hindrance T2 0.90 7 j5.17 4.84 11 j0.73 5.06 .15
QoL physical health T1 0.32 13 1.04 6.01 11 j0.58 3.91
QoL physical health T2 0.57 12 9.46 13.03 14 3.39 7.52 .16
QoL mental health T1 0.54 13 7.35 18.04 11 j1.46 14.70
QoL mental health T2 0.38 12 9.48 15.16 14 4.11 13.38 .39
Patient-related barriers toward pain management T1 1.62 14 j0.91 0.78 11 0.25 0.64
Patient-related barriers toward pain management T2 0.91 11 j0.50 0.84 14 0.13 0.51 .03c
Self-efficacy scale T1 0.51 14 0.14 2.25 11 j0.86 1.59
Self-efficacy scale T2 0.92 11 1.57 1.44 14 0.20 1.53 .23
Abbreviations: LMM, linear mixed model; IG, intervention group; CG, control group; T1, data collection time point 1, 1 week after discharge; T2, data
collection time point 2, 6 weeks after discharge; QoL, quality of life.
ad= 0.2, small effect; d=0.5, medium effect; d= 0.8, large effect.
bThe P value is given for the group-by-time interaction effect of the LMM.
cStatistically significant at the .05 level.
Table 4 & Number and Proportion of Patients With More Than 30% Improvement in Pain, Function-related
Outcomes, Health-related Quality of Life, Self-efficacy, and Patient-related Barriers Toward
Pain Management
IG CG
ImprovementQ30% ImprovementQ30%
n % (n) n % (n)
Average pain intensity T1 13 46.2 (6) 11 54.5 (6)
Average pain intensity T2 11 81.8 (9) 14 64.3 (9)
Worst pain intensity T1 13 46.2 (6) 11 81.8 (9)
Worst pain intensity T2 11 54.5 (6) 14 50.0 (7)
Pain interference with daily function T1 14 35.7 (5) 11 27.3 (3)
Pain interference with daily function T2 12 83.3 (10) 14 42.9 (6)
Pain-related activity hindrance T1 13 61.5 (8) 7 42.9 (3)
Pain-related activity hindrance T2 12 66.7 (8) 11 36.4 (4)
Health-related quality of life physical subscale T1 13 23.1 (3) 11 0
Health-related quality of life physical subscale T2 12 50.0 (6) 14 21.4 (3)
Health-related quality of life mental subscale T1 13 46.2 (6) 11 9.1 (1)
Health-related quality of life mental subscale T2 12 58.3 (7) 14 21.4 (3)
Patient-related barriers toward pain management T1 14 71.4 (10) 11 9.1 (1)
Patient-related barriers toward pain management T2 12 58.3 (7) 14 0.0 (0)
Self-efficacy T1 14 35.7 (5) 11 36.4 (4)
Self-efficacy T2 11 45.5 (5) 14 35.7 (5)
Abbreviations: CG, control group; IG, intervention group; T1, data collection time point 1, 1 week after discharge; T2, data collection time point 2, 6 weeks
after discharge.
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put a limit on life expectancy, estimates are often inaccurate.38
High dropout rates are probable in studies with oncology patients
with cancer pain. Therefore, we chose a statistical analysis that
allowed for the inclusion of all completed questionnaires
irrespective of the patient’s participation at subsequent data
collection time points. In future studies, the use of clinically
estimated life expectancy may be reconsidered. In patients with
advanced disease, low retention is particularly unfavorable
because these patients are potentially in special need of cancer
pain self-management support. Apart from a steadily decreasing
functional status that may prevent even highly motivated study
participants from proceeding with participation, study burden
may be a compounding factor. For these patients, the completion
of self-report questionnaires and additional meetings with inter-
vention nurses may present an extra challenge. With our pilot
study, we aimed at reducing study burden first, by using
telephone calls for follow-up, hence avoiding extra clinic visits
for pain management. Still, in a future study, measures will be
undertaken to integrate the intervention even more into routine
clinical practice. For example, bachelor-prepared ward nurses
will be trained to deliver the intervention and will be supported
in peer review meetings to integrate visits and telephone calls
into routine clinical care. Second, we determined meaningful
outcomes and covariates and ruled out more unimportant ones.39,40
For example, we will aim at shortening the German version
of the Barriers Questionnaire II in a future study. One-scale
instruments may be used instead of the long versions.41 In
addition, a minimally necessary data set may be defined
(eg, main outcome and only the most important demographic
variables) if patients cannot complete all questionnaires; data
collection may be performed via telephone if the completion of
questionnaires is not possible for the patients. This pilot study
provided the basis for the compilation of short and valid
questionnaires for a larger RCT.
Another challenge is that the pain etiology in a large number of
cancer patients is not chronic cancerYrelated but rather transient
treatment-related pain, for example, because of surgical interven-
tions. However, these patients are in need of pain-management
support for days to weeks. In fact, a subanalysis of our data showed
that surgical patients needed the follow-up telephone calls as long
as other patients did. In clinical practice, strategies to address all
kinds of cancer- and treatment-related pain are needed. The
ANtiPain intervention adequately addressed these patients’ needs.
Effect Sizes
The effect sizes for worst and average pain intensity remained in
the small to moderate range, which is plausible when compared
with effect sizes from previous meta-analyses.11,14 However,
effect sizes for function-related outcomes in our study were
large (eg, ‘‘pain-related activity hindrance’’). This is even more
significant in the light of an overall decrease of the objectively
measured functional status (ECOG) over the course of the
study. Importantly, differences in functional outcomes between
the IG and the CG also appeared to be clinically important,
which means that testing the effect in a larger study seems to be
worthwhile. Previous studies show that function-related out-
comes may be more important for patients than pain intensity.16,19,42
This means that the improvement of outcomes like pain-related
function and self-efficacy is a highly valuable contribution of the
ANtiPain intervention to cancer pain treatment. The lack of
statistical significance on functional outcomes is most probably
due to the small sample size and will be established when doing a
larger effectiveness study. These results will build the basis for the
statistical planning of a larger effectiveness study in which pain
intensity may still remain a secondary outcome. However, the
larger study may be powered for assessing pain-related function
as primary outcome as well as pain-related self-efficacy.
Opioid Intake
It has previously been supposed that the increase of opioid intake is
a key benchmark for adequate cancer pain treatment.2 Notably, in
this study, effects were achieved even though over the course of
the study, opioid doses of patients in the IG decreased compared
to patients in the CG.11,14,43 This is surprising at first sight.
However, it could be explained that in our patient population
with a high proportion of patients suffering from potentially
transient treatment-related cancer pain (ie postoperative pain),
patients were empowered by active self-management to reason-
ably adapt opioid doses to the actual need by active self-
surveillance and focused patient-physician communication.
The fact that patients in the IG used less opioids over time
may also reflect that strategies beyond knowledge transfer of
biomedical and pharmaceutical aspects of pain are extremely
important in cancer pain management.14,44
n Implications and Conclusions
Despite low functional status, 2 of 3 eligible patients were willing
to participate in the study. The core effects of the interventions
seem to involve function-related outcomes as well as self-efficacy.
Because these effects are most meaningful for patients with
cancer-related pain, the contribution of ANtiPain to physician-
based pharmaceutical cancer pain management may be excep-
tionally valuable. Therefore, ANtiPain may be a promising
intervention to improve cancer pain management when in-
tegrated into clinical practice. A larger clinical effectiveness
trial will be designed on the basis of the findings of this study,
which will focus on function-related outcomes and self-efficacy.
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